Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with hiv-1 infection

Publications

>

Article

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with hiv-1 infection

Publicated to:AIDS. 36 (1): 39-48 - 2022-01-01 36(1), DOI: 10.1097/QAD.0000000000003070

Authors: Cahn P; Sierra Madero J; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man CY; Urbaityte R; Brandon DJ; Underwood M; Pappa KA; Curtis L; Smith KY; Gartland M; Aboud M; Van Wyk J; Wynne B

Affiliations

Bliss Healthcare Serv, Orlando, FL USA - Author

Bliss Healthcare Services - Author

Fdn Huesped, Buenos Aires, DF, Argentina - Author

Fundación Huésped - Author

GlaxoSmithKline plc. - Author

GlaxoSmithKline, Stockley Pk, England - Author

Hop St Antoine, Paris, France - Author

Hopital Saint-Antoine - Author

Hosp Univ La Paz, Madrid, Spain - Author

Hospital Universitario La Paz - Author

Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico - Author

Instituto Nacional de la Nutricion Salvador Zubiran - Author

IRCCS Istituto Nazionale Malattie Infettive Lazzaro Spallanzani - Author

Ist Nazl Malattie Infett Lazzaro Spallanzani IRCC, Rome, Italy - Author

National Institutes of Health (NIH) - Author

National Taiwan University Hospital - Author

Natl Taiwan Univ Hosp, Taipei, Taiwan - Author

Royal Sussex County Hospital - Author

Royal Sussex Cty Hosp, Brighton & Sussex Med Sch, Brighton, E Sussex, England - Author

Univ Klinikum Bonn, Dept Med, Bonn, Germany - Author

Universitätsklinikum Bonn - Author

ViiV Healthcare - Author

ViiV Healthcare, 5 Moore Dr,POB 13398, Res Triangle Pk, NC 27709 USA - Author

ViiV Healthcare, Brentford, England - Author

Abstract

Objective:To assess efficacy and safety of dolutegravir (DTG) + lamivudine (3TC) vs. DTG + tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naive adults with HIV-1 in the prespecified 144-week secondary analyses of GEMINI-1 and GEMINI-2.Design:Identical, multicenter, phase III, randomized, non-inferiority studies (double-blind through 96 weeks).Methods:Participants with HIV-1 RNA ≤500 000 copies/ml and no major viral resistance mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, or protease inhibitors were randomized 1:1 to once-daily DTG + 3TC or DTG + TDF/FTC.Results:At week 144, DTG + 3TC (N = 716) was noninferior to DTG + TDF/FTC (N = 717) in proportion of participants achieving HIV-1 RNA <50 copies/ml (Snapshot algorithm) in the pooled analysis (82% vs. 84%, respectively; adjusted treatment difference [95% confidence interval (CI)], -1.8% [-5.8, 2.1]), GEMINI-1 (-3.6% [-9.4, 2.1]), and GEMINI-2 (0.0% [-5.3, 5.3]). Twelve DTG + 3TC participants and nine DTG + TDF/FTC participants met protocol-defined confirmed virologic withdrawal (CVW) criteria; none developed treatment-emergent resistance. One DTG + 3TC participant who did not meet CVW criteria developed M184V at week 132 and R263R/K at week 144, conferring a 1.8-fold change in susceptibility to DTG; non-adherence to therapy was reported. Significantly fewer drug-related adverse events occurred with DTG + 3TC vs. DTG + TDF/FTC (20% vs. 27%; relative risk [95% CI], 0.76 [0.63-0.92]). Renal and bone biomarker changes favored DTG + 3TC.Conclusions:Three-year durable efficacy, long-term tolerability, and high barrier to resistance support first-line use of DTG + 3TC for HIV-1 treatment (see Supplemental Digital Content 1, http://links.lww.com/QAD/C297; video abstract).

Keywords

DolutegravirIntegrase strand transfer inhibitorNucleoside reverse transcriptase inhibitorTreatment-naiveTwo-drug regimen

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal AIDS due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Infectious Diseases.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 9.28. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

Weighted Average of Normalized Impact by the Scopus agency: 13.18 (source consulted: FECYT Feb 2024)
Field Citation Ratio (FCR) from Dimensions: 26.84 (source consulted: Dimensions Jun 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-06-30, the following number of citations:

WoS: 41
Scopus: 87
Europe PMC: 24

Impact and social visibility

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Argentina; France; Germany; Iran; Italy; Mexico; Taiwan; United Kingdom; United States of America.

Indexed in

License and use

Citations

Altmetrics

Analysis of institutional authors

Share

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with hiv-1 infection

Affiliations

Abstract

Keywords

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

Impact and social visibility

Leadership analysis of institutional authors